Abstract

34P Treatment sequencing in the VISION study of tepotinib in patients with MET exon 14 (METex14) skipping NSCLC

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Case report: Response to tepotinib in Chinese non-small cell lung cancer patients harboring METex14 skipping with varying features.
Yan Meng ... Meiqing Wang
Frontiers in Oncology | VOL. 14
Yan Meng, et. al.Yan Meng ... Meiqing Wang
02 Jul 2024
81 - Tepotinib in patients with MET exon 14 (METex14) skipping NSCLC: results from the VISION study and local UK experience
Wanyuan Cui ... Paul Paik
Lung cancer (Amsterdam, Netherlands) | VOL. 165
Wanyuan Cui, et. al.Wanyuan Cui ... Paul Paik
10 Feb 2022
24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy
F Griesinger ... P Paik
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 33
F Griesinger, et. al.F Griesinger ... P Paik
01 Apr 2022
PP01.83 Treatment Sequencing in the VISION Study of Tepotinib in Patients with MET exon 14 (METex14) Skipping NSCLC
Frank Griesinger ... Paul K Paik
Journal of Thoracic Oncology | VOL. 19
Frank Griesinger, et. al.Frank Griesinger ... Paul K Paik
01 Jul 2024
View more papers

More From: Journal of Thoracic Oncology

Paper Title
Journal
Date
Author
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC
Soyeong Jun ... Maximilian Diehn
Journal of Thoracic Oncology | VOL. -
Soyeong Jun, et. al.Soyeong Jun ... Maximilian Diehn
05 Jul 2024
PP01.133 Clinical and Economic Outcomes Associated with Genomic Testing Strategies in Real-World Data in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Benjamin Levy ... Teddy Saliba
Journal of Thoracic Oncology | VOL. 19
Benjamin Levy, et. al.Benjamin Levy ... Teddy Saliba
01 Jul 2024
PP01.99 Switching to Subcutaneous (SC) Atezolizumab After Intravenous (IV) Dosing: Evaluation of Atezolizumab Pharmacokinetics (PK) Using Population PK Modeling
Stephanie N Liu ... Benjamin Wu
Journal of Thoracic Oncology | VOL. 19
Stephanie N Liu, et. al.Stephanie N Liu ... Benjamin Wu
01 Jul 2024
PP01.11 Real-world treatment patterns and outcomes among unresectable Stage III Non-Small Cell Lung Cancer
Ashwini Arunachalam ... Jerome Goldschmidt
Journal of Thoracic Oncology | VOL. 19
Ashwini Arunachalam, et. al.Ashwini Arunachalam ... Jerome Goldschmidt
01 Jul 2024
View more papers